Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

    Not Recruiting
  • participants needed
  • sponsor
    Regeneron Pharmaceuticals
Updated on 20 June 2021


The primary objective of the study is to demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) with alirocumab subcutaneous (SC) every 2 weeks (Q2W) in comparison to placebo after 12 weeks of treatment.

The secondary objectives of the study are:

  • To evaluate the effect of alirocumab Q2W on other lipid parameters (ie, apolipoprotein [Apo] A-1 and B, non-high-density lipoprotein cholesterol [non-HDL-C], total-cholesterol [TC], proportion of participants with 15%, 30%, and 50% LDL-C reductions, Lp(a), HDL-C, triglycerides [TG]) in participants with HoFH
  • To evaluate the safety and tolerability of alirocumab SC Q2W in participants with HoFH
  • To assess the pharmacokinetics of alirocumab SC Q2W in participants with HoFH
  • To assess the potential development of anti-drug (alirocumab) antibodies

Condition Homozygous Familial Hypercholesterolemia
Treatment Placebo, alirocumab
Clinical Study IdentifierNCT03156621
SponsorRegeneron Pharmaceuticals
Last Modified on20 June 2021

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note